Psoriasis drug shows promise for kids in Real-World study
NCT ID NCT06142357
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 200 children aged 6 to 17 with moderate-to-severe plaque psoriasis who are taking secukinumab (Cosentyx). Researchers want to see how long patients stay on the drug, how well it controls their psoriasis, and how tolerable it is. The study collects data from the past and tracks patients going forward to get a real-world picture of the treatment's effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Secukinumab (Cosentyx)
What this could lead to
If successful, this study could confirm that secukinumab is a reliable long-term treatment option for children with moderate-to-severe plaque psoriasis.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It also only includes children already prescribed the drug, which may introduce bias.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Chelyabinsk, 454048, Russia
-
Novartis Investigative Site
Grozny, 364022, Russia
-
Novartis Investigative Site
Izhevsk, 426009, Russia
-
Novartis Investigative Site
Kazan', 420012, Russia
-
Novartis Investigative Site
Kemerovo, 650025, Russia
-
Novartis Investigative Site
Moscow, 105007, Russia
-
Novartis Investigative Site
Moscow, 117513, Russia
-
Novartis Investigative Site
Moscow, 119296, Russia
-
Novartis Investigative Site
Moscow, 119435, Russia
-
Novartis Investigative Site
Mytishchi, 141009, Russia
-
Novartis Investigative Site
Nizhny Novgorod, 603950, Russia
-
Novartis Investigative Site
Rostov-on-Don, 344022, Russia
-
Novartis Investigative Site
Tolyatti, 445846, Russia
-
Novartis Investigative Site
Tula, 300053, Russia
-
Novartis Investigative Site
Ufa, 450000, Russia
-
Novartis Investigative Site
Yakutsk, 677000, Russia